JPH04501719A - ポリペプチド - Google Patents

ポリペプチド

Info

Publication number
JPH04501719A
JPH04501719A JP1511698A JP51169889A JPH04501719A JP H04501719 A JPH04501719 A JP H04501719A JP 1511698 A JP1511698 A JP 1511698A JP 51169889 A JP51169889 A JP 51169889A JP H04501719 A JPH04501719 A JP H04501719A
Authority
JP
Japan
Prior art keywords
item
items
cells
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1511698A
Other languages
English (en)
Japanese (ja)
Inventor
テイラー―パパデイミトリオウ，ジヨイス
ジエンドラー，サンドラ
バーチエル，ジヨイ
Original Assignee
インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888826362A external-priority patent/GB8826362D0/en
Priority claimed from GB898907660A external-priority patent/GB8907660D0/en
Application filed by インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド filed Critical インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Publication of JPH04501719A publication Critical patent/JPH04501719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP1511698A 1988-11-10 1989-11-10 ポリペプチド Pending JPH04501719A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8826362.9 1988-11-10
GB888826362A GB8826362D0 (en) 1988-11-10 1988-11-10 Polypeptide
GB898907660A GB8907660D0 (en) 1989-04-05 1989-04-05 Polypeptide
GB8907660.8 1989-04-05

Publications (1)

Publication Number Publication Date
JPH04501719A true JPH04501719A (ja) 1992-03-26

Family

ID=26294608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1511698A Pending JPH04501719A (ja) 1988-11-10 1989-11-10 ポリペプチド

Country Status (3)

Country Link
EP (1) EP0442926A1 (de)
JP (1) JPH04501719A (de)
WO (1) WO1990005142A1 (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341252B1 (de) * 1987-01-07 1997-11-19 Imperial Cancer Research Technology Limited Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
EP0636029B1 (de) * 1992-04-13 2000-11-08 Dana-Farber Cancer Institute, Inc. Gegen karzinom-assoziierte antigene gerichtete antikörper
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU2247095A (en) * 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
AU684348B2 (en) * 1994-06-07 1997-12-11 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and adioactive therapeutic agent containing the peptide
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
DK1027063T3 (da) 1997-09-29 2009-06-02 Macfarlane Burnet Inst For Med Mannosereceptorbærende cellelinje og antigensammensætning
EP1369428A1 (de) * 1997-10-31 2003-12-10 Biomira Inc. Muc-1 Derivate und deren Verwendung bei der Behandlung von mit Krebs-assoziierter MUC-1 Mucin-induzierter Immunosuppression
JP2002526380A (ja) * 1997-10-31 2002-08-20 バイオミラ，インコーポレイテッド 癌関連ｍｕｃ−１ムチン誘発免疫抑制の治療におけるｍｕｃ−１誘導体とその使用法
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
AU2003223775A1 (en) 2002-04-30 2003-11-17 Duke University Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
PE20061329A1 (es) 2004-12-15 2006-12-08 Neuralab Ltd Anticuerpos ab humanizados para mejorar la cognicion
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US8889641B2 (en) 2009-02-11 2014-11-18 The University Of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
US9409953B2 (en) 2011-02-10 2016-08-09 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
PL2900686T3 (pl) 2012-09-28 2021-01-25 The University Of North Carolina At Chapel Hill Wektory aav ukierunkowane na oligodendrocyty
AU2014227766B2 (en) 2013-03-15 2018-10-04 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV vectors
EP3517612A1 (de) 2013-03-15 2019-07-31 The University of North Carolina At Chapel Hill Synthetische adenoassoziierte virusinvertierte endwiederholungssequenzen
EP4344741A3 (de) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Auf das zentrale nervensystem gerichtete aav-vektoren
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
WO2016127057A1 (en) 2015-02-06 2016-08-11 The University Of North Carolina At Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
IL314171A (en) 2015-09-28 2024-09-01 Univ Florida Methods and compositions for antibody-evading virus vectors
US10801041B2 (en) 2015-11-18 2020-10-13 Orbis Health Solutions, Llc T7 alpha viral vector system
BR112018011881A2 (pt) 2015-12-14 2018-12-04 The University Of North Carolina At Chapel Hill proteínas capsidiais modificadas para liberação aumentada de vetores de parvovírus
IL316259A (en) 2017-03-15 2024-12-01 Univ North Carolina Chapel Hill Polyploid gland associated with virus vectors and methods for preparing and using the same.
CA3092107A1 (en) 2018-02-28 2019-09-06 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
WO2019195423A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
WO2019195444A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Antibody-evading virus vectors
JP7406677B2 (ja) 2018-04-03 2023-12-28 ギンコ バイオワークス インコーポレイテッド 抗体を回避するウイルスベクター
US12410441B2 (en) 2018-06-12 2025-09-09 The University Of North Carolina At Chapel Hill Synthetic liver-tropic adeno-associated virus capsids and uses thereof
CA3104113A1 (en) 2018-06-22 2019-12-26 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
US20220194992A1 (en) 2019-04-26 2022-06-23 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
AU2020367532A1 (en) 2019-10-17 2022-05-12 Ginkgo Bioworks, Inc. Adeno-associated viral vectors for treatment of Niemann-Pick disease type C
KR20220083708A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 Aav 전달 카세트
MX2022013819A (es) 2020-05-05 2023-01-30 Univ North Carolina Chapel Hill Capsides de virus adeno-asociado 5 modificado y usos del mismo.
MX2023002016A (es) 2020-08-19 2023-06-26 Sarepta Therapeutics Inc Vectores de virus adenoasociados para el tratamiento del sindrome de rett.
AU2021369480B2 (en) 2020-10-28 2025-05-22 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding AAV2.5 vector
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
CA3216491A1 (en) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
TW202511280A (zh) 2023-07-21 2025-03-16 義大利商博雷亞醫療有限責任公司 製備表面修飾之病毒外殼之方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0341252B1 (de) * 1987-01-07 1997-11-19 Imperial Cancer Research Technology Limited Humane polymorphe epitheliale mucin polypeptide zur verwendung in therapie und diagnose

Also Published As

Publication number Publication date
WO1990005142A1 (en) 1990-05-17
EP0442926A1 (de) 1991-08-28

Similar Documents

Publication Publication Date Title
US12338272B2 (en) High avidity antigen recognizing constructs
US6344203B1 (en) Mimicking peptides in cancer therapy
WO1990005142A1 (en) Polypeptides
ES2240981T3 (es) Citocina denominada lerk-7.
ES2652017T3 (es) Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer
US9452204B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes
US7268207B2 (en) Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
JPH09501159A (ja) 合成多重縦列反復ムチンおよびムチン様ペプチド、並びにそれらの利用
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JPH09505723A (ja) ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列
US20020091234A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
JP2021521817A5 (de)
WO2011091716A1 (zh) 表皮生长因子受体变异体
CN111378039A (zh) 治疗恶性肿瘤的抗体及其应用
CN115109160A (zh) 抗epcam抗体和双特异性抗体
Liang et al. Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group
CN1082053A (zh) 合成多肽
EP1167387A1 (de) Anti-SEMP1-Antikörper, Verfahren zu deren Herstellung, und deren Anwendungen
US20050063970A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
CN102127147B (zh) 表皮生长因子受体模拟表位肽及其应用
JP2005513040A (ja) Ｔｌｐペプチドを含む融合タンパク質
Xing et al. Peptide epitopes in breast cancer mucins
JP4037451B2 (ja) 大腸細胞および大腸癌細胞関連核酸分子、タンパク質およびペプチド